Literature DB >> 19708902

Causes of morbidity among HIV-infected children on antiretroviral therapy in primary care facilities in Lusaka, Zambia.

Mwangelwa Mubiana-Mbewe1, Carolyn Bolton-Moore, Yolan Banda, Namwinga Chintu, Mutinta Nalubamba-Phiri, Mark Giganti, M Brad Guffey, Pauline Sambo, Elizabeth M Stringer, Jeffrey S A Stringer, Benjamin H Chi.   

Abstract

OBJECTIVES: To describe the pattern of incident illness in children after initiation of antiretroviral therapy (ART) in a large public health sector programme in Lusaka, Zambia.
METHODS: Systematic chart review to retrospectively extract data from medical records of children (i.e. <15 years) initiating ART in the Lusaka, Zambia public sector. Incident conditions were listed separately and then grouped according to broad categories. Predictors for incident diagnoses were determined using univariate and multivariable analysis.
RESULTS: Between May 2004 and June 2006, 1705 HIV-infected children initiated ART. Of these, 1235 (72%) had their medical records reviewed. Median age at ART initiation was 77 months and 554 (45%) were females. Eight hundred and forty-one (68%) children had an incident condition during this period, with a median time of occurrence of 64 days from ART initiation. Twenty-eight incident conditions were documented. When categorized, the most common were mucocutaneous conditions [incidence rate (IR): 70.6 per 100 child-years, 95% CI: 64.5-77.2] and upper respiratory tract infection (IR: 70.1 per 100 child-years; 95% CI: 64.0-76.7). Children with severe immunosuppression (i.e. CD4 < 10%) were more likely to develop lower respiratory tract infection (16.3%vs. 10.2%; P = 0.003) and mucocutaneous conditions (43.9% vs. 35.3%; P = 0.005) than those with CD4 > or = 10%.
CONCLUSION: There is a high incidence of new illness after ART initiation, emphasizing the importance of close monitoring during this period. Early initiation of ART and use of antimicrobial prophylaxis may also help to reduce the occurrence of such co-morbidities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19708902      PMCID: PMC3897250          DOI: 10.1111/j.1365-3156.2009.02360.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  22 in total

1.  Increased incidence of cutaneous mycoses after HAART initiation: a benign form of immune reconstitution disease?

Authors:  Mathieu Nacher; Vincent Vantilcke; Aba Mahamat; Myriam El Guedj; Tania Vaz; Andry Randrianjohany; Emmanuel Clyti; Christine Aznar; Bernard Carme; Pierre Couppié
Journal:  AIDS       Date:  2007-10-18       Impact factor: 4.177

2.  Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in Sub-Saharan Africa.

Authors: 
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-15       Impact factor: 3.731

3.  Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.

Authors:  Heather B Jaspan; Alison E Berrisford; Andrew M Boulle
Journal:  Pediatr Infect Dis J       Date:  2008-11       Impact factor: 2.129

4.  Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study.

Authors:  Chifumbe Chintu; Victor Mudenda; Sebastian Lucas; Andrew Nunn; Kennedy Lishimpi; Daniel Maswahu; Francis Kasolo; Peter Mwaba; Ganapati Bhat; Hiroshi Terunuma; Alimuddin Zumla
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

5.  Meeting international goals in child survival and HIV/AIDS.

Authors:  Neff Walker; Bernhard Schwartländer; Jennifer Bryce
Journal:  Lancet       Date:  2002-07-27       Impact factor: 79.321

6.  Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children.

Authors:  Myron J Levin; Jeffrey P Anderson; George R Seage; Paige L Williams
Journal:  J Acquir Immune Defic Syndr       Date:  2009-02-01       Impact factor: 3.731

7.  Early antiretroviral therapy and mortality among HIV-infected infants.

Authors:  Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre
Journal:  N Engl J Med       Date:  2008-11-20       Impact factor: 91.245

8.  Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland.

Authors:  Addy Kekitiinwa; Katherine J Lee; A Sarah Walker; Albert Maganda; Katja Doerholt; Sabrina B Kitaka; Alice Asiimwe; Ali Judd; Philippa Musoke; Diana M Gibb
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-01       Impact factor: 3.731

9.  Use of task-shifting to rapidly scale-up HIV treatment services: experiences from Lusaka, Zambia.

Authors:  Mary B Morris; Bushimbwa Tambatamba Chapula; Benjamin H Chi; Albert Mwango; Harmony F Chi; Joyce Mwanza; Handson Manda; Carolyn Bolton; Debra S Pankratz; Jeffrey S A Stringer; Stewart E Reid
Journal:  BMC Health Serv Res       Date:  2009-01-09       Impact factor: 2.655

10.  Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy.

Authors:  Elisabetta Walters; Mark F Cotton; Helena Rabie; H Simon Schaaf; Lourens O Walters; Ben J Marais
Journal:  BMC Pediatr       Date:  2008-01-11       Impact factor: 2.125

View more
  9 in total

Review 1.  Tackling HIV through robust diagnostics in the developing world: current status and future opportunities.

Authors:  Darash Desai; Grace Wu; Muhammad H Zaman
Journal:  Lab Chip       Date:  2010-12-01       Impact factor: 6.799

2.  Opportunistic and other infections in HIV-infected children in Latin America compared to a similar cohort in the United States.

Authors:  Jorge O Alarcón; Laura Freimanis-Hance; Margot Krauss; Mary F Reyes; Claudete Aparecida Araújo Cardoso; Marisa M Mussi-Pinhata; Edmundo Cardoso; Rohan Hazra
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-19       Impact factor: 2.205

3.  Morbidity and health care resource utilization in HIV-infected children after antiretroviral therapy initiation in Côte d'Ivoire, 2004-2009.

Authors:  Sophie Desmonde; Jean-Bosco Essanin; Addi E Aka; Eugène Messou; Madeleine Amorissani-Folquet; Virginie Rondeau; Andrea Ciaranello; Valériane Leroy
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

4.  Single genome amplification of proviral HIV-1 DNA from dried blood spot specimens collected during early infant screening programs in Lusaka, Zambia.

Authors:  Lillian Seu; Innocent Mwape; M Bradford Guffey
Journal:  J Virol Methods       Date:  2014-03-22       Impact factor: 2.014

5.  High Viremia and Wasting Before Antiretroviral Therapy Are Associated With Pneumonia in Early-Treated HIV-Infected Kenyan Infants.

Authors:  Geetha Sridharan; Dalton Wamalwa; Grace John-Stewart; Kenneth Tapia; Agnes Langat; Helen Moraa Okinyi; Judith Adhiambo; Daisy Chebet; Elizabeth Maleche-Obimbo; Catherine J Karr; Sarah Benki-Nugent
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

6.  Costs of Care of HIV-Infected Children Initiating Lopinavir/Ritonavir-Based Antiretroviral Therapy before the Age of Two in Cote d'Ivoire.

Authors:  Sophie Desmonde; Divine Avit; Junie Petit; Madeleine Amorissani Folquet; Francois Tanoh Eboua; Clarisse Amani Bosse; Evelyne Dainguy; Véronique Mea; Marguerite Timite-Konan; Sylvie Ngbeché; Andrea Ciaranello; Valeriane Leroy
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

Review 7.  Underutilisation of routinely collected data in the HIV programme in Zambia: a review of quantitatively analysed peer-reviewed articles.

Authors:  Tendai Munthali; Patrick Musonda; Paul Mee; Sehlulekile Gumede; Ab Schaap; Alwyn Mwinga; Caroline Phiri; Nathan Kapata; Charles Michelo; Jim Todd
Journal:  Health Res Policy Syst       Date:  2017-06-13

8.  Time-varying age- and CD4-stratified rates of mortality and WHO stage 3 and stage 4 events in children, adolescents and youth 0 to 24 years living with perinatally acquired HIV, before and after antiretroviral therapy initiation in the paediatric IeDEA Global Cohort Consortium.

Authors:  Sophie Desmonde; Anne M Neilan; Beverly Musick; Gabriela Patten; Kulkanya Chokephaibulkit; Andrew Edmonds; Stephany N Duda; Karen Malateste; Kara Wools-Kaloustian; Andrea L Ciaranello; Mary-Ann Davies; Valériane Leroy
Journal:  J Int AIDS Soc       Date:  2020-10       Impact factor: 5.396

9.  Mortality in a Cohort of HIV-Infected Children: A 12-Month Outcome of Antiretroviral Therapy in Makurdi, Nigeria.

Authors:  Emmanuel Ademola Anigilaje; Sunday Adedeji Aderibigbe
Journal:  Adv Med       Date:  2018-06-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.